Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01629329 · ClinicalTrials.gov registry record · Phase 4
Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine
A Phase 4 study, sponsored by Albert Einstein Healthcare Network.
- Terminated
- Registry status
- Phase 4
- Development phase
- 93
- Enrollment target
NCT01629329: Clinical Trial Phase 4 study, sponsored by Albert Einstein Healthcare Network.
NCT01629329 is a Phase 4 study that was terminated before completion, run by Albert Einstein Healthcare Network. The registered enrollment target is 93 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01629329, a Phase 4 study, was terminated before completion, sponsored by Albert Einstein Healthcare Network.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 93 participants
- Enrollment target
Study Summary
The objective of this randomized, double blind study is to demonstrate that one dose oral "excedrin migraine" (acetaminophen, aspirin and caffeine) is not inferior when compared to one dose of intravenous prochlorperazine for the treatment of acute migraine headaches in the emergency department.
Primary Outcome
0 Participants analyzed. PI has left the institution. Efforts made to contact were unsuccessful. No data available
Interventions
- DRUG Aspirin, Acetaminophen, Caffeine pills
- DRUG Prochlorperazine 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-07 |
| Phase | Phase 4 |
Why NCT01629329 stopped before completion
NCT01629329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Aspirin, Acetaminophen, Caffeine pills is the first listed.
NCT01629329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01629329 about?
NCT01629329 is a clinical study titled "Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine". The objective of this randomized, double blind study is to demonstrate that one dose oral "excedrin migraine" (acetaminophen, aspirin and caffeine) is not inferior when compared to one dose of intravenous prochlorperazine for the treatment of acute migraine headaches in the emergency department.
What is the current status of trial NCT01629329?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2010-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01629329?
The interventions under investigation include: Aspirin, Acetaminophen, Caffeine pills (DRUG), Prochlorperazine 10mg (DRUG).
Who is sponsoring clinical trial NCT01629329?
This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01629329's enrollment target sits among peer trials
93 874th of 2000 higher than 1,125 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia